

Factors Associated With Fatigue After Surgery in Women With Early-Stage Invasive Breast Cancer

CHRISTINE ROTONDA,^{a,b,c,d} FRANCIS GUILLEMIN,^{a,b,c,d} FRANCK BONNETAIN,^{d,e} MICHEL VELTEN,^{d,f} THIERRY CONROY^{c,d,g}

^aINSERM, CIC-EC, CIE6, Nancy, France; ^bDepartment of Clinical Epidemiology and Evaluation Department, CHU Nancy, Vandoeuvre-lès-Nancy, France; ^cUniversité de Lorraine, Université Paris Descartes, EA 4360 APEMAC, Nancy, France; ^dQuality of Life in Oncology Platform, France; ^eBiostatistic and Epidemiological Unit, Centre Georges-François Leclerc, University of Burgundy, Dijon, France; ^fDepartment of Epidemiology and Biostatistics, Centre Paul Strauss, University of Strasbourg, Strasbourg, France; ^gDepartment of Medical Oncology, Centre Alexis Vautrin, Vandoeuvre-lès-Nancy, France

Disclosures of potential conflicts of interest may be found at the end of this article.

Learning Objectives

Describe the effect of worsening fatigue after breast cancer surgery on physical functioning and psychological distress.

Better identify women at risk for developing cancer-related fatigue.

Direct target interventions to patients most in need.

ABSTRACT

Purpose. Fatigue is one of the most frequent symptoms in patients with cancer. However, the precise determinants of fatigue are still unknown. This study was conducted to investigate factors correlated with cancer-related fatigue before surgery and just before subsequent adjuvant therapy.

Methods. Patients completed the Multidimensional Fatigue Inventory (MFI-20), the European Organization for Research and Treatment of Cancer 30-item quality-of-life questionnaire before and after surgery, the Trait Anxiety Inventory and the Life Orientation Test before surgery, and the State Anxiety Inventory before the start of adjuvant therapy. Multiple regression analysis of determinants of change in MFI-20 total score after surgery was conducted.

Results. A series of 466 eligible patients with stage I–III breast cancer with planned surgery were recruited. An increase in MFI-20 total score after surgery was significantly correlated

with higher preoperative fatigue and lower role functioning before surgery; a decrease in role functioning, physical functioning, and cognitive functioning after surgery; an increase in insomnia after surgery; and a higher state anxiety after surgery. Disease stage, lymph node metastases, surgical procedure, and demographic characteristics (e.g., age, marital status, having children, educational level) were not correlated with fatigue in multivariate analysis.

Conclusion. These results suggest that worsening fatigue after surgery for breast cancer is associated with a decrease in physical functioning and an increase in psychological distress rather than with the cancer characteristics. Therefore, screening measures should be implemented at the time of diagnosis—before starting treatment—to identify psychologically vulnerable patients and to offer them professional support. *The Oncologist* 2013;18:467–475

Implications for Practice: To decrease fatigue after surgery, it is necessary to account for the level of cancer-related fatigue, to assess the presence of correlates, and to provide guidelines when developing intervention strategies for helping breast cancer patients to prevent and to limit this symptom. In addition, screening measures should be implemented at the time of diagnosis, before starting breast cancer treatment, to identify psychologically vulnerable patients and to offer them professional support.

INTRODUCTION

Breast cancer is the most common malignant disorder among women. Approximately 350,000 new cases of breast cancer are registered in Europe annually [1]. An early mammography screening program, early diagnosis, and improvement in therapeutic strategies have increased the life expectancy of these patients. Ensuring the well-being of patients has become one of the aims of treatment. Quality of life (QoL), along with other

patient-reported outcomes, has become one of the primary outcomes to assess the efficiency of the new cancer therapies [2].

Surgical treatment is usually the initial treatment for invasive early stage of breast cancer. Surgical options include breast-conserving therapy or mastectomy. Sentinel lymph node biopsy has become an alternative procedure to axillary node dissection [3, 4]. Patients undergoing surgery have been

Correspondence: Christine Rotonda, Ph.D., Inserm CIC-EC CIE6, Clinical Epidemiology and Evaluation Department, Allée du Morvan, 54505 Vandoeuvre-lès-Nancy, France. Telephone: +33 3 83 85 20 92; Fax: +33 3 83 85 12 05; E-mail: c.rotonda@chu-nancy.fr Received July 13, 2012; accepted for publication November 1, 2012; first published online in *The Oncologist Express* on February 12, 2013. ©AlphaMed Press 1083-7159/2013/\$20.00/0 <http://dx.doi.org/10.1634/theoncologist.2012-0300>

observed to experience significant QoL changes and have been found to become more anxious and to develop sleep difficulties [5, 6]. Several studies have compared QoL associated with breast-conserving surgery versus mastectomy and conflicting results have been reported [7–9]. Nevertheless, two of the most commonly reported consequences of breast cancer surgery are pain and postoperative fatigue [6, 10], which could impair QoL. Although postsurgical pain has been the focus of many studies, fatigue has been more rarely investigated [11, 12].

Fatigue is considered to be a multidimensional concept with several modes of expression: physical (e.g., diminished energy), cognitive (e.g., diminished concentration or attention), and affective (e.g., decreased motivation or interest). It involves chronic exhaustion and diminished capacity for physical activity that is not relieved by rest [13].

Several factors could contribute to cancer-related fatigue, including direct effects of cancer, adverse effects of cancer treatment, psychological factors such as personality traits (e.g., optimism, anxiety, depression), comorbid physical symptoms, comorbid medical conditions, and lifestyle factors, such as physical activity practice [14–16]. The majority of studies examining determinants of cancer-related fatigue have focused on adjuvant therapy or breast cancer survivors [17]. To our knowledge, no study to date has investigated determinants of fatigue before surgery as predictors of fatigue evolution after surgery. Furthermore, no study has examined the relationship between personality factors (optimism and trait anxiety) before treatment and fatigue in patients with breast cancer having surgery. Nevertheless, understanding specific predictors of change in cancer-related fatigue is a necessary step for developing effective interventions to reduce and/or alleviate fatigue. Furthermore, identifying a comprehensive set of factors before surgery and before subsequent adjuvant therapy would enable clinicians to better identify women at risk for developing cancer-related fatigue for targeted interventions.

In the present study, we tested the following research hypotheses:

1. An increase in cancer-related fatigue after surgery might be associated with a decrease in most postoperative functioning domains of QoL.
2. A lower level of optimism before surgery might be associated with an increase in postoperative cancer-related fatigue.
3. Higher preoperative trait anxiety might be associated with worse fatigue after surgery.
4. Lifestyle factors, such as physical activity, might be related to a reduced risk of developing fatigue after surgery [18–20].

Thus, the aim of this study was to identify factors associated with change in cancer-related fatigue before subsequent adjuvant therapy in patients with breast cancer in a longitudinal cohort study.

METHODS

The present study is part of the FATSEIN study (“FATigue dans le cancer du SEIN”), an investigation of patients with breast cancer [21]. This prospective longitudinal study was designed to examine cancer-related fatigue in women who received adjuvant therapy for early-stage breast cancer. Protocol details

have been previously published and extensively described elsewhere [21].

Eligibility criteria included the following: women newly diagnosed with invasive breast cancer, undergoing breast surgery as primary treatment, 18 years of age or older, no history of other cancers, able to read and write French, able to provide informed consent, no other major disabling medical or psychiatric conditions that would confound evaluation of QoL and fatigue, no previous chemotherapy or radiotherapy, no metastases, and no inflammatory breast cancer.

Sampling

All patients who met the eligibility criteria were informed about the study on the day preceding surgery (at baseline T_0). FATSEIN study’s inclusion was conducted between August 2008 and January 2011 in three French cancer care centers. For this study, we examined the data collected on two occasions: T_0 , the day preceding surgery (at baseline); and T_1 , after surgery and just before subsequent adjuvant treatment.

Data Collection

At inclusion, patients completed the Multidimensional Fatigue Inventory (MFI-20), the European Organization for Research and Treatment of Cancer 30-item QoL questionnaire (EORTC QLQ-C30), the Life Orientation Test (LOT), and the Trait Anxiety Inventory (STAI-Trait). Before adjuvant therapy, patients completed again the MFI-20, the EORTC QLQ-C30, and the STAI-State.

Fatigue Outcome

Fatigue was assessed by a 20-item questionnaire, the MFI-20 [22]. It consists of four scales based on different dimensions: general/physical fatigue, reduced activity, reduced motivation, and mental fatigue. Each item of each subscale was answered on a 5-point Likert scale (1: true to 5: not true). The score of each four-item subscale was obtained as the sum of the scores on four items. Each subscale and the total score of the MFI-20 are standardized on a scale from 0 to 100, with higher scores indicating more fatigue.

In the absence of established guidelines and to interpret the meaningful clinical change in MFI-20 scores, we used the minimal clinically important difference as defined for the EORTC QLQ-C30 scale [23]. A mean change/difference of 5–10 in the MFI-20 score is considered to be a small change, 10–20 a moderate change, and >20 a very large change.

Other Variables

Quality of Life.

The EORTC QLQ-C30 questionnaire is a well-validated QoL instrument [24]. The questionnaire consists of 30 items on five functional scales that evaluate physical, role, emotional, cognitive, and social functioning; nine symptom scales that measure fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, and diarrhea; as well as financial difficulties and a global QoL scale. Scores are standardized to 0–100 scales, in which higher scores are indicative of a higher level of functioning or a higher level of symptom disturbance.

Optimism.

Optimism was measured using the LOT, a 12-item questionnaire [25]. Participants indicated the extent of their agreement with each item from 1 (strongly disagree) to 5 (strongly

agree). After reversing scoring for negatively worded items, scores can be summed up to yield an overall score. The score is standardized on a scale from 0 to 100. Higher scores indicate greater optimism and lower scores indicate lesser optimism (referred to as pessimism).

Anxiety.

The STAI is a 40-item instrument measuring transient (STAI Y-A state anxiety) and enduring levels of anxiety (STAI Y-B trait anxiety) [26]. According to the developers, state anxiety may fluctuate over time and can vary in intensity, in contrast with trait anxiety, which denotes “relatively stable individual differences in anxiety proneness” and refers to a general tendency to respond with anxiety to perceived threats in the environment [26]. The trait version (STAI Y-B) consists of 20 statements that assess how patients feel “generally.” Patients respond to each item on a 4-point Likert scale (almost never, sometimes, often, and almost always). For the state version (STAI Y-A), patients indicate for 20 items on 4-point Likert scale (not at all, somewhat, moderately so, very much so) the extent to which they are currently experiencing each symptom of anxiety. In the present study, only trait anxiety was assessed postsurgery. State anxiety was assessed at each presurgery measurement. Each subscale STAI is standardized on a scale from 0 to 100, with higher scores indicating a higher level of anxiety.

Data concerning sociodemographics, medical history, type of surgery, tumor size on pathological examination, and adjuvant treatment were obtained from medical records. Information on physical activity was collected at each assessment. Patients were asked if they practiced a physical activity (yes/no). Daily help (and the number of hours per week) was also collected at each assessment.

Statistical Analyses

Descriptive statistics (frequencies, percentages, means, standard deviations, and ranges) were generated to characterize the study sample. At baseline, patient’s sociodemographic and clinical characteristics and questionnaire scores were compared according to patients’ participation (patients who participated vs. those that withdrew). The Wilcoxon nonparametric test was used to evaluate group scores differences. The percentage of missing questionnaires and missing items for fatigue’s questionnaire was provided. Only women who provided information in T_0 and in T_1 could be included for the comparison.

The differences between MFI-20 total scores over time for cancer-related fatigue and between each QoL score over time were calculated. The Wilcoxon nonparametric test was used to evaluate differences. In addition, we assessed the number of clinically relevant changes in fatigue and in QoL (differences of 10 points or more) from T_0 to T_1 . Bivariate associations between presurgery predictor variables and change in cancer-related fatigue and between change in QoL scores and change in cancer-related fatigue were examined using the Pearson correlation coefficient.

A multicollinearity analysis was completed to determine whether candidate variables were strongly associated with each other. The variance inflation factors (VIF) were calculated. A VIF >4 was generally considered to indicate severe multicollinearity. The global QoL scale of QLQ-C30 has been shown to be a significant predictor; intuitively, it is expected to

be most affected by multicollinearity [27, 28]. QLQ-C30 fatigue scale and MFI-20 scales might also cause multicollinearity problems. Therefore, these variables were not included in the multivariate analysis, except for cancer-related fatigue at baseline. Other significant variables ($p \leq .1$) were included in the model. Stepwise regression analysis was used to determine the independent variables that contributed significantly to variance in change in cancer-related fatigue. The variables that were significantly different between centers were forced into the multivariate analyses. Sequential bootstrap resampling was implemented to evaluate stability of the model. Data were analyzed using software (SAS version 9.2, SAS Institute, Cary, NC). For all tests, the type I error was set to 0.05 and all tests were two-sided.

RESULTS

Between August 2008 and January 2011, 556 patients were included. After surgery, 26 women (4.7%) were excluded because invasive breast cancer was not pathologically confirmed; 58 (10.4%) patients dropped out because they withdrew consent and major protocol violation was observed for 6 (1.1%) patients. Therefore, 466 patients were followed. Table 1 shows the demographic and clinical characteristics of the patients.

There were no significant differences in demographic and clinical characteristics between patients who completed the study and those who withdrew. Patients who dropped out had higher scores for the reduced motivation ($p = .004$) scale of MFI-20, lower scores for the emotional functioning scale of QLQ-C30 ($p = .046$), and higher scores for nausea ($p = .026$).

The average time between the two measures was less than 2 months (mean = 47 days, SD = 17 days). Intervals between surgery and first chemotherapy treatment and delays between surgery and beginning of radiotherapy were not significantly different (50 ± 19 days and 46 ± 14 days, respectively; $p = .11$). Patients treated by hormonotherapy alone or without adjuvant treatment ($n = 26$) had a significantly shorter delay between the two measures (38 ± 11 days, $p = .002$).

Missing Data

Before surgery, 98.5%, 98.3%, 98.9%, and 97.2% of the patients completed the MFI-20, QLQ-C30, LOT, and STAI Y-B questionnaires, respectively. After surgery, 88.2% of the patients completed the MFI-20 and QLQ-C30 questionnaires; 87.5% of patients completed the state anxiety questionnaire. No differences between patients who completed questionnaires and patients who did not were found. We observed a very low rate of missing items concerning the fatigue questionnaire (0.89% missing items before surgery and 0.79% after surgery).

Course of Fatigue and Quality of Life Before and After Surgery

Table 2 shows the mean values and standard deviation for the questionnaire scores before and after surgery and the mean change in scores. Scores for all subscales of the MFI-20 significantly increased after surgery. Moderate reductions (score difference superior to 10 points) in the MFI-20 activity and motivation dimensions were reported by 43% and 39% of the patients, respectively.

The physical, role, and social functioning scores of the QLQ-C30 significantly decreased after surgery ($p < .0001$). Pa-

Table 1. Baseline patient demographics and clinical characteristics ($n = 466$)

Characteristic	<i>n</i> (%)
Age, median yrs (range)	57.0 (28–84)
Marital status	
Single	34 (7.5)
Married/live-in relationship	339 (74.7)
Divorced	45 (9.9)
Widowed	36 (7.9)
Unknown	12
Children	
None	48 (10.5)
≤ 2	287 (62.7)
> 2	123 (26.9)
Unknown	8
Living with children ≤ 18 years	28 (11.9)
Distance between home and hospital	
< 50 km	168 (36.1)
≥ 50 km	286 (61.4)
Unknown	12
Education level	
Less than compulsory school	6 (1.5)
Compulsory school education	207 (50.7)
Postcompulsory school but not university	85 (20.8)
University level	110 (27.0)
Unknown	58
Employment status	
Employed	264 (57.8)
Unemployed	50 (10.8)
Retired	143 (31.3)
Unknown	9
Menopausal status	
Premenopausal	150 (33.2)
Postmenopausal, with hormone substitution treatment of the menopause	58 (12.8)
Postmenopausal, without hormone substitution treatment	244 (54.0)
Unknown	14
Mean age at menopause (SD)	49.7 (6.5)
Daily help	
Yes	44 (10.1)
No	390 (89.9)
Unknown	32
Physical activity	
Yes	256 (60.4)
No	168 (39.6)
Unknown	42
Surgical procedure	
Lumpectomy	362 (78.2)
Mastectomy	101 (21.8)
Unknown	3
Axillary procedure	
No axillary dissection	12 (2.6)
Sentinel lymph node biopsy	229 (49.5)
Axillary dissection	137 (29.6)
Sentinel lymph node biopsy and axillary dissection	85 (18.4)
Unknown	3

Table 1. Continued

Characteristic	<i>n</i> (%)
Disease stage	
Stage I	239 (53.2)
Stage II	180 (40.3)
Stage III	29 (6.5)
Unknown	18
Type of planned adjuvant therapy	
None	2 (0.5)
Hormonotherapy alone	24 (5.1)
Chemotherapy alone	20 (4.4)
Radiation	178 (39.5)
Combination chemotherapy and radiation	185 (41.0)
Combination chemotherapy (with or without radiation) and trastuzumab	42 (8.7)
Unknown	15
Anemia (hemoglobin level < 12 g/dL)	
Yes	15 (3.3)
No	339 (75.3)
No data	96 (21.3)
Unknown	16

Data are *n* (%) unless otherwise specified.
Abbreviation: SD, standard deviation.

tients reported a significantly poorer global health status/QoL score after surgery ($p = .0002$). The emotional functioning score improved after surgery ($\Delta_{T1-T0} = 7.3, p = .0001$). A total of 49% of patients reported a moderate decrease in the role functioning dimension. The mean scores for fatigue ($p < .0001$), pain ($p < .0001$), nausea and vomiting ($p = .003$), constipation ($p = .001$), and financial difficulties ($p = .0002$) increased significantly after surgery. We also observed that 47% and 21% of patients presented with moderate increases in pain and insomnia, respectively.

Postoperatively, patients who had undergone mastectomy reported lower scores of role, physical, and social functioning on EORTC QLQ-C30 scales than those who had had a lumpectomy (mean score, role functioning: 65.3 [SD: 26.2] vs. 73.2 [SD: 25.9], $p = .01$; mean score, physical functioning: 77.6 [SD: 17.9] vs. 82.5 [SD: 16.4], $p = .014$; mean score, social functioning: 76.1 [SD: 25.4] vs. 82.4 [SD: 22.6], $p = .02$). Patients who underwent mastectomy also reported more nausea/vomiting (mean score: 9.5 [SD: 21.6] vs. 5.1 [SD: 12.2]; $p = .01$) and more appetite loss (mean score: 18.2 [SD: 30.1] vs. 10.8 [SD: 21.3]; $p = .01$) after surgery and were less optimistic (mean score: 61.4 [SD: 15.2] vs. 65.8 [SD: 13.8]; $p = .01$). For the other QLQ-C30 scales, MFI-20, trait anxiety, and state anxiety, no other significant differences of the scores were observed.

Factors Associated With Change in Fatigue

According to our hypothesis, QoL and QLQ-C30 and MFI-20 fatigue scale scores might produce harmful multicollinearity (VIF ≥ 4). Therefore, these variables were eliminated from the final analysis because collinearity can increase estimates of parameter variance. Significant correlations existed among the other independent variables but none were considered to be multicollinear.

Table 3 presents variables significantly associated with change in cancer-related fatigue after surgery in bivariate and

Table 2. Questionnaire scores before and after surgery

	Before surgery (T ₀)	After surgery (T ₁)	Difference T ₁ – T ₀	p value (Wilcoxon test)
MFI-20^a				
General/physical fatigue	28.1 (22.9)	36.0 (23.7)	7.9 (21.2)	<.0001
Reduced activity	22.0 (20.9)	38.0 (23.2)	16.5 (24.0)	<.0001
Reduced motivation	22.2 (24.9)	30.8 (27.1)	7.9 (25.5)	<.0001
Mental fatigue	25.0 (22.7)	29.6 (23.1)	3.9 (20.6)	.003
Total score	25.7 (19.8)	33.8 (21.0)	8.0 (18.1)	<.0001
QLQ-C30				
Functional scales ^b				
Physical	89.8 (14.0)	81.5 (16.8)	–8.6 (14.2)	<.0001
Role	88.6 (19.6)	71.6 (26.1)	–17.3 (28.6)	<.0001
Emotional	61.7 (25.1)	68.2 (24.1)	7.3 (24.6)	.0001
Cognitive	84.4 (19.5)	83.4 (20.5)	–0.5 (19.4)	.49
Social	92.2 (17.2)	81.1 (23.3)	–11.3 (23.7)	<.0001
Global QoL/GHS	71.0 (19.8)	67.2 (19.2)	–4.9 (19.5)	.0002
Symptom scales ^c				
Fatigue	24.2 (21.9)	33.9 (22.7)	10.0 (23.1)	<.0001
Pain	11.6 (18.5)	25.7 (24.5)	13.6 (26.2)	<.0001
Nausea and vomiting	3.4 (10.7)	6.0 (14.8)	2.5 (17.0)	.003
Other items ^c				
Sleep disturbance	44.2 (34.8)	40.0 (31.9)	–4.1 (37.4)	.06
Dyspnea	14.0 (22.8)	14.7 (23.3)	0.3 (21.5)	.64
Diarrhea	9.5 (19.0)	6.5 (17.2)	–3.2 (21.4)	.01
Appetite loss	12.0 (22.5)	12.4 (23.6)	–0.6 (27.2)	.76
Constipation	11.2 (22.6)	16.7 (27.6)	5.2 (26.9)	.001
Financial difficulties	4.9 (15.9)	9.5 (20.0)	4.8 (18.0)	.0002
LOT score ^d	64.8 (14.2)			
STAI Y-B score ^e	34.1 (15.9)			
STAI Y-A score ^e		34.4 (21.8)		

Data are means (SD) unless noted.

^aHigher score indicates more fatigue.

^bHigher score represents a higher level of functioning or better quality of life.

^cHigher score indicates more symptoms/problems.

^dHigher score indicates greater optimism.

^eHigher score indicates a higher level of trait and state anxiety.

Abbreviations: LOT, Life Orientation Test; MFI, Multidimensional Fatigue Inventory; QLQ, Quality-of-Life Questionnaire; QoL/GHS, Quality of Life/Global Health Score; SD, standard deviation; STAI Y-B, Trait Anxiety Inventory; STAI Y-A, State Anxiety Inventory.

multivariate analyses. Bivariate statistics showed a strong association between a decrease in all functional scores of QLQ-C30 and an increased MFI-20 total score between T₀ and T₁ ($p < .0001$). Lower physical ($p = .01$), role ($p = .003$), emotional ($p < .0001$), cognitive ($p < .0001$), and social ($p = .0005$) functioning scales and lower global health status/QoL scale ($p = .002$) of QLQ-C30 measured before surgery and lower preoperative MFI-20 total score were also associated with an increase in cancer-related fatigue after surgery. Worsening pain, sleep disturbance, appetite loss (all $p < .0001$), and nausea/vomiting ($p = .0005$) were strongly associated with a worsening in fatigue.

Optimism was not associated with change in fatigue after surgery. Higher preoperative trait anxiety and postoperative state-anxiety were associated with an increase in cancer-related fatigue ($p = .001$ and $p = .004$, respectively). Daily help after surgery was not significantly associated with change in

cancer-related fatigue ($p = .08$). Neither sociodemographic factors (age, marital status, having children at home, employment status, educational level) nor disease and treatment pattern (stage of disease, lymph node metastases, surgical procedure, type of planned adjuvant therapy) were significantly related to change in cancer-related fatigue. A center effect was nearly observed ($p = .051$). The comparison of demographical clinical characteristics between centers showed some variables were significantly different. Center effect and these variables were forced in the multivariate model.

Multiple regression analyses showed that worsening in cancer-related fatigue level before and after surgery was best predicted by higher cancer-related fatigue ($p < .0001$) and lower role functioning ($p = .0008$) before surgery; by deterioration in role, cognitive, and physical functioning ($p < .0001$, $p = .02$, and $p = .0003$, respectively) after surgery; by an in-

Table 3. Factors associated with change in MFI-20 total score after surgery (bivariate and multivariate analyses, regression model; $n = 466$)

Factor	Bivariate analysis			Multivariate analysis			Multivariate analysis with bootstrap procedure		
	β	p	r^2	β	p	Adjusted r^2	β	p	Adjusted r^2
Clinical characteristics									
Daily help after surgery (yes vs. no)	-3.81	.08	0.008						
Disease stage			0.008						
I vs III	-6.43	.09							
II vs III	-6.81	.08							
Center effect		.051	0.015		0.06	.006			
Trait anxiety	-0.18	.0014	0.02						
MFI-20 total score before surgery	-0.35	<.0001	0.15	-0.51	<.0001	.15	-0.53	<.0001	0.18
QLQ-C30 scores before surgery									
Functional scales									
Physical	0.17	.01	0.02						
Role	0.14	.003	0.02	-0.15	.0008	0.02	-0.13	<.0001	0.02
Emotional	0.14	<.0001	0.04						
Cognitive	0.18	<.0001	0.04	-0.09	.10	0.005			
Social	0.19	.0005	0.03						
Global QoL/GHS ^a	0.14	.002	0.02						
Symptom scales/items									
Fatigue ^a	-0.17	<.0001	0.04						
Sleep disturbance	-0.06	.015	0.014						
Constipation	0.08	.04	0.01	0.06	.09	0.005			
Change in QLQ-C30 scores after surgery									
Change in functional scales ^b									
Physical	-0.50	<.0001	0.15	-0.13	.0003	0.03			
Role	-0.27	<.0001	0.18	-0.21	<.0001	0.21	-0.19	<.0001	0.20
Emotional	-0.28	<.0001	0.14						
Cognitive	-0.32	<.0001	0.12	-0.15	.02	0.01	-0.13	<.0001	0.02
Social	-0.25	<.0001	0.11						
Global QoL/GHS ^a	-0.39	<.0001	0.18						
Change in symptom scales/items									
Fatigue ^a	0.41	<.0001	0.28						
Pain	0.19	<.0001	0.07						
Sleep disturbance	0.12	<.0001	0.06	0.06	.001	0.02	0.11	<.0001	0.05
Dyspnea	0.10	.02	0.01						
Appetite loss	0.18	<.0001	0.07						
Nausea/vomiting	0.18	.0005	0.03						
State anxiety measured after surgery	0.12	.004	0.02	0.15	<.0001	0.04	0.13	<.0001	0.05
r^2 total						0.50			0.52

Abbreviations: MFI, Multidimensional Fatigue Inventory; QLQ, Quality-of-Life Questionnaire; QoL/GHS, Quality of Life/Global Health Score.

^aVariables not included in multivariate analyses.

^bDifference of $T_1 - T_0$.

crease in insomnia after surgery ($p = .001$); and by a higher state anxiety after surgery ($p < .0001$; Table 3). Subsequent analysis with variables selected through bootstrapping procedures revealed that physical functioning was not any more associated with change in cancer-related fatigue and confirmed that the best predictors of a worsening in cancer-related fatigue were higher cancer-related fatigue and lower role functioning before surgery, a deterioration in role and cognitive functioning, a higher sleep disturbance

after surgery, and a higher state anxiety after surgery (all $p < .0001$; Table 3).

DISCUSSION

As in previous studies [29, 30], participants in this study reported elevated levels of postoperative fatigue and their activity was strongly reduced. Patients rated their role functioning, social functioning, and QoL lower; their functional well-being also showed significant deterioration.

Patients also reported significantly increased pain, constipation, and nausea/vomiting.

The strongest predictors for an increase of fatigue after surgery were lower role functioning before surgery, higher preoperative cancer-related fatigue, higher state anxiety after surgery, an increase in insomnia, and a decrease in QoL in most domains. It is important to note that presurgical fatigue and a worsening in role functioning accounted for 20% and 18%, respectively, of the variance in change in postsurgical fatigue.

According to our hypothesis, decreases in role, physical, and cognitive functioning would be predictors of an increase in cancer-related fatigue after surgery. Following the use of a sequential bootstrap technique that evaluated the precision of estimation, only changes in role and cognitive function demonstrated a strong association with cancer-related fatigue. Similar to Ancoli-Israel et al. [31], we found that a worsening in sleep disturbance was associated with a worsening in fatigue after surgery. Before treatments start, the baseline levels of sleep and circadian rhythms must be determined to limit fatigue during and after treatment.

Contrary to another study [32], we did not show that pain level was associated with worsening fatigue after surgery. Pain has a number of negative effects on mood, daily activities, sleep, cognitive functions, social life, and long-term QoL [11]. The number of dissected lymph nodes, type of surgery, and age may play an active role in the development of pain after breast cancer surgery, although the results are conflicting [33, 34].

Some studies showed that women who underwent mastectomies were more fatigued than women who underwent lumpectomies [35]. In addition, undergoing mastectomy was a significant predictor of cancer-related fatigue in a recent study [32]. This result can be explained by the possible psychological impact of mastectomy. In our study, type of surgery was not found to influence fatigue after surgery, but only 22% of our patients had mastectomies. Nevertheless, we observed that patients who had undergone mastectomies reported lower role, physical, and social functioning; had greater appetite loss; and were less optimistic than patients who had lumpectomies.

Our results suggest also that patients with breast cancer who presented with greater fatigue before surgery have a greater risk of experiencing postsurgical fatigue. Consequently, it might be beneficial to screen such patients prior to surgery to reduce their postsurgical cancer-related fatigue. It was previously suggested that emotional support is important at the time of diagnosis and after surgery [36]. Indeed, social and family support and communication have been found to be important factors, which may be partially responsible for better QoL and therefore less fatigue. In our study, social support and emotional functioning were correlated with fatigue; however, when these factors had to compete with others factors, the positive association did not hold. Another study also found that social support did not appear to play a role in fatigue measured 6 months after surgery [37].

Our study focused on two personality traits: optimism and trait anxiety. Optimism has been defined as a general-

ized tendency to have positive expectancies for the future [25, 38]. Some studies assessed the relationship between optimism and cancer-related fatigue in patients with breast cancer [16, 39]. They found that greater optimism was related to lower cancer-related fatigue in a longitudinal sample of patients with breast cancer who were interviewed postoperatively and over the next year [40]. Our results do not confirm the association between optimism before surgery and postsurgery cancer-related fatigue.

Literature indicates that patients with cancer have higher preoperative anxiety than patients without cancer [41]. The diagnosis of cancer induces stresses that are caused by the patient's perception of cancer and treatment. This state anxiety may fluctuate over time and can vary in intensity. Lehto and Cimprich investigated the relationship between anxiety and directed attention (the ability to focus and concentrate) in women awaiting breast cancer surgery [42]. They concluded that health care professionals should assess anxiety in women during the preoperative period and assist them in coping with the psychological and cognitive demands associated with this highly stressful period.

In contrast to the transitory nature of state anxiety, trait anxiety reflects the disposition to experience anxiety in threatening situations. Studies have reported that trait anxiety assessed prior to diagnosis was a significant predictor of depressive symptoms, fatigue [43], and QoL [44] in women with breast complaints 6 months after the diagnosis of a benign breast problem or surgery to treat breast cancer. Greater trait anxiety and state anxiety were associated with an increase in cancer-related fatigue after surgery in bivariate analysis; however, in multivariate analysis, only state anxiety (i.e., the level of momentary anxiety) was significantly associated with change in cancer-related fatigue. The personality traits of patients did not have a significant influence on change in fatigue immediately after surgery. The relationship between personality trait and fatigue needs to be more fully explored, particularly in longitudinal studies.

Literature shows that higher fatigue after surgery is associated with lower physical activity [18, 19]. Indeed, De Jong et al. examined the course of the activity level in patients with breast cancer who were receiving adjuvant chemotherapy; an increase in fatigue accompanied by a reduction in activity level was reported [45]. A reduced functional capacity means that patients with breast cancer expend greater effort relative to maximal ability to perform usual activities, thus leading to higher level of fatigue. Exercise training attenuates the loss and even increases functional capacity.

A number of studies on patients with breast cancer during and after their adjuvant treatment have investigated the effects of physical activity in reducing cancer-related fatigue, with no definitive conclusions regarding its effectiveness [46]. Nevertheless, exercise seems to be beneficial for patients with breast cancer, and the evidence suggesting that physical activity limits cancer-related fatigue is particularly strong [47]. To our knowledge, the current study is the first to seek physical activity prior to surgery as a predictor of change in cancer-related fatigue after surgery. How-

ever, in multivariate analysis, the association between physical activity and fatigue was not significant. Nevertheless, physical activity was analyzed as a dichotomous variable and no validated questionnaire was used. Further research about this association is necessary.

Some limitations of this study must be discussed. The first limitation of this study might be attrition bias. The sample of patients who dropped out is small (10%), but these patients were significantly less motivated than followed patients. Secondly, we did not include data on comorbidities, such as diabetes, and other chronic conditions that could affect fatigue.

Our results suggest that changes in cancer-related fatigue after surgery in patients with breast cancer are determined by physical and psychological distress rather than by the clinical characteristics of the cancer. This study indicates the cross-sectional and short-term longitudinal association of various variables and changes in fatigue after surgery, but it is difficult to infer causal relationship. Long-term follow-up studies should be conducted to explore the impact of demographics, medical history, and personality traits on fatigue at different stages of disease and treatment.

CONCLUSIONS

Waiting for surgery is a very stressful experience for patients with breast cancer. Preoperative experiences and coping with breast cancer have postoperative impacts. To decrease fatigue after surgery, it is necessary to account for the level of cancer-related fatigue, assess the presence of correlates, and provide guidelines when developing intervention strategies

for supporting these patients. In addition, screening measures should be implemented at the time of diagnosis, before the beginning of breast cancer treatment, to identify psychologically vulnerable patients and offer them professional support. More recently, some authors suggested that introduction of palliative care services earlier in the course of the disease could have a meaningful positive effect on patients' QoL and moods [48, 49]. The early integration of palliative care in the disease trajectory of patients is explicitly recommended by the World Health Organization. Nevertheless, these hypotheses require further study.

ACKNOWLEDGMENTS

This study was supported by the Lorraine Regional Council, Cancéropôle du Grand-Est, and Nancy University Hospital.

AUTHOR CONTRIBUTIONS

Conception/Design: Christine Rotonda, Francis Guillemin, Franck Bonnetain, Thierry Conroy

Provision of study material or patients: Franck Bonnetain, Michel Velten, Thierry Conroy

Collection and/or assembly of data: Christine Rotonda

Data analysis and interpretation: Christine Rotonda, Francis Guillemin, Franck Bonnetain, Michel Velten, Thierry Conroy

Manuscript writing: Christine Rotonda, Francis Guillemin, Franck Bonnetain, Michel Velten, Thierry Conroy

Final approval of manuscript: Christine Rotonda, Francis Guillemin, Franck Bonnetain, Michel Velten, Thierry Conroy

DISCLOSURES

Gabriel Hortobágyi: Antigen Express, Galena Biopharma, Novartis, Rockpointe (C/A); Novartis (RF); Taivex (O); founder and member of the board of directors for Citizen's Oncology Foundation; Kathleen Pritchard: Novartis, Roche, AstraZeneca, Pfizer, Boehringer-Ingelheim, GlaxoSmithKline, Sanofi, Ortho-Biotech, Amgen, Bristol-Myers Squibb (C/A), (H).

Reviewer "A": None
Reviewer "B": None

REFERENCES

- Tyczynski JE, Plesko I, Aareleid T et al. Breast cancer mortality patterns and time trends in 10 new EU member states: mortality declining in young women, but still increasing in the elderly. *Int J Cancer* 2004;112:1056–1064.
- Roila F, Cortesi E. Quality of life as a primary end point in oncology. *Ann Oncol* 2001;12 (suppl 3):S3–S6.
- Lyman GH, Giuliano AE, Somerfield MR et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. *J Clin Oncol* 2005;23:7703–7720.
- McCready D, Holloway C, Shelley W et al. Surgical management of early stage invasive breast cancer: A practice guideline. *Can J Surg* 2005;48:185–194.
- Arora NK, Gustafson DH, Hawkins RP et al. Impact of surgery and chemotherapy on the quality of life of younger women with breast carcinoma: A prospective study. *Cancer* 2001;92:1288–1298.
- Dabakuyo TS, Fraisse J, Causeret S et al. A multicenter cohort study to compare quality of life in breast cancer patients according to sentinel lymph node biopsy or axillary lymph node dissection. *Ann Oncol* 2009;20:1352–1361.
- Han J, Grothuesmann D, Neises M et al. Quality of life and satisfaction after breast cancer operation. *Arch Gynecol Obstet* 2010;282:75–82.
- Nissen MJ, Swenson KK, Ritz LJ et al. Quality of life after breast carcinoma surgery: A comparison of three surgical procedures. *Cancer* 2001;91:1238–1246.
- Pandey M, Thomas breast cancer, Ramdas K et al. Early effect of surgery on quality of life in women with operable breast cancer. *J Clin Oncol* 2006;36:468–472.
- Wyatt GK, Friedman LL. Physical and psychosocial outcomes of midlife and older women following surgery and adjuvant therapy for breast cancer. *Oncol Nurs Forum* 1998;25:761–768.
- Gartner R, Jensen MB, Nielsen J et al. Prevalence of and factors associated with persistent pain following breast cancer surgery. *JAMA* 2009;302:1985–1992.
- Katz J, Poleshuck EL, Andrus CH et al. Risk factors for acute pain and its persistence following breast cancer surgery. *Pain* 2005;119:16–25.
- Cella D, Lai JS, Chang CH et al. Fatigue in cancer patients compared with fatigue in the general United States population. *Cancer* 2002;94:528–538.
- Bower JE, Ganz PA, Desmond KA et al. Fatigue in breast cancer survivors: Occurrence, correlates, and impact on quality of life. *J Clin Oncol* 2000;18:743–753.
- Stone P, Richards M, A'Hern R et al. A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. *Ann Oncol* 2000;11:561–567.
- Von Ah DM, Kang DH, Carpenter JS. Predictors of cancer-related fatigue in women with breast cancer before, during, and after adjuvant therapy. *Cancer Nurs* 2008;31:134–144.
- De Jong N, Courtens AM, Abu-Saad HH et al. Fatigue in patients with breast cancer receiving adjuvant chemotherapy: A review of the literature. *Cancer Nurs* 2002;25:283–297.
- Berger AM, Farr L. The influence of daytime inactivity and nighttime restlessness on cancer-related fatigue. *Oncol Nurs Forum* 1999;26:1663–1671.
- Berger AM, Higginbotham P. Correlates of fatigue during and following adjuvant breast cancer chemotherapy: A pilot study. *Oncol Nurs Forum* 2000;27:1443–1448.
- Jacobsen PB, Hann DM, Azzarello LM et al. Fatigue in women receiving adjuvant chemotherapy for breast cancer: Characteristics, course, and correlates. *J Pain Symptom Manage* 1999;18:233–242.
- Rotonda C, Guillemin F, Bonnetain F et al. Factors correlated with fatigue in breast cancer patients before, during and after adjuvant chemotherapy: The FATSEIN study. *Contemp Clin Trials* 2011;32:244–249.
- Gentile S, Delarozziere JC, Favre F et al. Validation of the French multidimensional fatigue inventory (MFI 20). *Eur J Cancer Care (Engl)* 2003;12:58–64.
- Osoba D, Rodrigues G, Myles J et al. Interpreting the significance of changes in health-related quality-of-life scores. *J Clin Oncol* 1998;16:139–144.
- Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instru-

ment for use in international clinical trials in oncology. *J Natl Cancer Inst* 1993;85:365–376.

- 25.** Scheier MF, Carver CS. Optimism, coping, and health: Assessment and implications of generalized outcome expectancies. *Health Psychol* 1985;4:219–247.
- 26.** Spielberger CD. *State-Trait Anxiety Inventory: A comprehensive bibliography*. Mountain View, CA: Consulting Psychologists Press, 1989.
- 27.** Dancey J, Zee B, Osoba D et al. Quality of life scores: An independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. *Qual Life Res* 1997;6:151–158.
- 28.** Van SK, Curran D, Kramer J et al. Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: Identification and impact on model selection. *Stat Med* 2002;21:3865–3884.
- 29.** Deboss J, Riis JO, Pedersen L et al. Cognitive function and quality of life after surgery for early breast cancer in North Jutland, Denmark. *Acta Oncol* 2009;48:532–540.
- 30.** Rubin GJ, Hardy R, Hotopf M. A systematic review and meta-analysis of the incidence and severity of postoperative fatigue. *J Psychosom Res* 2004;57:317–326.
- 31.** Ancoli-Israel S, Liu L, Marler MR et al. Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer. *Support Care Cancer* 2006;14:201–209.
- 32.** Haghghat S, Akbari ME, Holakouei K et al. Factors predicting fatigue in breast cancer patients. *Support Care Cancer* 2003;11:533–538.
- 33.** Hack TF, Cohen L, Katz J et al. Physical and psychological morbidity after axillary lymph node dissection for breast cancer. *J Clin Oncol* 1999;17:143–149.
- 34.** Wallace MS, Wallace AM, Lee J et al. Pain after breast surgery: A survey of 282 women. *Pain* 1996;66:195–205.
- 35.** De Jong N, Candel MJ, Schouten HC et al. Prevalence and course of fatigue in breast cancer patients receiving adjuvant chemotherapy. *Ann Oncol* 2004;15:896–905.
- 36.** Arora NK, Finney Rutten LJ et al. Perceived helpfulness and impact of social support provided by family, friends, and health care providers to women newly diagnosed with breast cancer. *Psychooncology* 2007;16:474–486.
- 37.** De Vries J, Van der Steeg AF, Roukema JA. Determinants of fatigue 6 and 12 months after surgery in women with early-stage breast cancer: A comparison with women with benign breast problems. *J Psychosom Res* 2009;66:495–502.
- 38.** Scheier MF, Carver CS, Bridges MW. Distinguishing optimism from neuroticism (and trait anxiety, self-mastery, and self-esteem): A reevaluation of the Life Orientation Test. *J Pers Soc Psychol* 1994;67:1063–1078.
- 39.** Carver CS, Pozo C, Harris SD et al. How coping mediates the effect of optimism on distress: A study of women with early stage breast cancer. *J Pers Soc Psychol* 1993;65:375–390.
- 40.** Carver CS, Lehman JM, Antoni MH. Dispositional pessimism predicts illness-related disruption of social and recreational activities among breast cancer patients. *J Pers Soc Psychol* 2003;84:813–821.
- 41.** McCleane GJ, Cooper R. The nature of pre-operative anxiety. *Anaesthesia* 1990;45:153–155.
- 42.** Lehto RH, Cimprich B. Anxiety and directed attention in women awaiting breast cancer surgery. *Oncol Nurs Forum* 1999;26:767–772.
- 43.** De Vries J, Van der Steeg AF, Roukema JA. Trait anxiety determines depressive symptoms and fatigue in women with an abnormality in the breast. *Br J Health Psychol* 2009;14:143–157.
- 44.** Van der Steeg AF, De VJ, Van der Ent FW et al. Personality predicts quality of life six months after the diagnosis and treatment of breast disease. *Ann Surg Oncol* 2007;14:678–685.
- 45.** De Jong N, Kester AD, Schouten HC et al. Course of fatigue between two cycles of adjuvant chemotherapy in breast cancer patients. *Cancer Nurs* 2006;29:467–477.
- 46.** Mock V, Frangakis C, Davidson NE et al. Exercise manages fatigue during breast cancer treatment: A randomized controlled trial. *Psychooncology* 2005;14:464–477.
- 47.** Kirshbaum MN. A review of the benefits of whole body exercise during and after treatment for breast cancer. *J Clin Nurs* 2007;16:104–121.
- 48.** Gaertner J, Wuerstlein R, Klein U et al. Integrating palliative medicine into comprehensive breast cancer therapy: A pilot project. *Breast Care* 2011;6:215–220.
- 49.** Temel JS, Greer JA, Muzikansky A et al. Early palliative care for patients with metastatic non-small-cell lung cancer. *N Engl J Med* 2010;363:733–742.

CME

This article is available for continuing medical education credit at CME.TheOncologist.com.